The ARF tumour suppressor

被引：72

作者：

Gallagher, Stuart J. ^{[1
]}

Kefford, Richard F. ^{[1
]}

Rizos, Helen ^{[1
]}

机构：

[1] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia

来源：

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2006年 / 38卷 / 10期

关键词：

senescence; p53; pathway; nucleolus; SUMO; melanoma; INK4alARF;

D O I：

10.1016/j.biocel.2006.02.008

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The ARF tumour suppressor is a product of the INK4alARF locus; a sequence that is frequently altered in human cancer. ARF is upregulated by oncogenic stimuli and is a critical regulator of p53 stability through interactions with the mdm2 and ARF-BP1/Mule ubiquitin ligases. Cellular stress signals liberate ARF from the nucleolus where it is bound to B23/nucleophosmin. This nucleolar location of ARF may serve as a reservoir for the rapid induction of p53, but may also serve to co-ordinate effects on cell cycle, survival and growth. The biological functions of ARF interactions with other binding partners remain uncertain, but ARF-mediated sumoylation may represent a unifying effector pathway. (c) 2006 Elsevier Ltd. All rights reserved.

引用

收藏

页码：1637 / 1641

页数：5

相关论文

共 15 条

[1] ARF-BP1/mule is a critical mediator of the ARF tumor suppressor [J].

Chen, DL ;

Kon, N ;

Li, MY ;

Zhang, WZ ;

Qin, J ;

Gu, W .

CELL, 2005, 121 (07) :1071-1083

[2]

DURO D, 1995, ONCOGENE, V11, P21

[3] A mutation hotspot at the p14ARF splice site [J].

Harland, M ;

Taylor, CF ;

Chambers, PA ;

Kukalizch, K ;

Randerson-Moor, JA ;

Gruis, NA ;

de Snoo, FA ;

ter Huurne, JAC ;

Goldstein, AM ;

Tucker, MA ;

Bishop, DT ;

Bishop, JAN .

ONCOGENE, 2005, 24 (28) :4604-4608

[4] Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation [J].

Itahana, K ;

Bhat, KP ;

Jin, AW ;

Itahana, Y ;

Hawke, D ;

Kobayashi, R ;

Zhang, YP .

MOLECULAR CELL, 2003, 12 (05) :1151-1164

[5] Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function [J].

Korgaonkar, C ;

Hagen, J ;

Tompkins, V ;

Frazier, AA ;

Allamargot, C ;

Quelle, FW ;

Quelle, DE .

MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (04) :1258-1271

[6] Multiple domains of the mouse P19ARF tumor suppressor are involved in p53-independent apoptosis [J].

Matsuoka, M ;

Kurita, M ;

Sudo, H ;

Mizumoto, K ;

Nishimoto, I ;

Ogata, E .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 301 (04) :1000-1010

[7] Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I [J].

Olivier, A ;

Lucie, K ;

Jean-François, R ;

Christian-Jacques, L ;

Paule, S .

ONCOGENE, 2003, 22 (13) :1945-1954

[8] p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners [J].

Rizos, H ;

Woodruff, S ;

Kefford, RF .

CELL CYCLE, 2005, 4 (04) :597-603

[9] p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor [J].

Rocha, S ;

Campbell, KJ ;

Perkins, ND .

MOLECULAR CELL, 2003, 12 (01) :15-25

[10] Stability of nucleolar versus non-nucleolar forms of human p14ARF [J].

Rodway, H ;

Llanos, S ;

Rowe, J ;

Peters, G .

ONCOGENE, 2004, 23 (37) :6186-6192